The High-Risk Human Papillomavirus Type Influences the Tissue Microenvironment in Cervical Intraepithelial Neoplasia Grade 2

High-risk, cancer-causing human papillomavirus (HPV) types are associated with cervical precancer and cancer. A high proportion of high-risk HPV precancer lesions undergo immune-mediated regression. The purpose of this study was to determine if the tissue microenvironment of HPV16 and 18 (HPV16/18) cervical intraepithelial neoplasia grade 2 lesions differed from other high-risk types (HPV ‘other’). Consistent with other studies, we found that progression to higher-grade disease was more frequent in HPV16/18 lesions when compared with HPV ‘other’ lesions. HPV16/18 lesions were significantly more likely to be indoleamine 2,3,-dioxygenase 1 (IDO1)-positive and were associated with reduced CD8 and FoxP3 T cells in the lesion. In the stroma, reduced Tbet- and CD32-positive cells and increased Blimp1-positive cells were significantly associated with HPV16/18 lesions when compared with HPV ‘other’ types. On analysis of the IDO1-positive tissues, lesional IDO1 was associated with significantly decreased numbers of CD4-, CD8-, and FoxP3-positive cells in the stroma compared with IDO1-negative tissues. These data suggest that IDO1 expression may impair infiltration of CD4, CD8, and FoxP3 cells into the stroma beneath the precancer lesion. Increased expression of IDO1 may contribute to immune avoidance and an increased frequency of disease progression in HPV16- and 18-positive lesions.

[1]  J. Califano,et al.  Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway , 2023, Cell reports.

[2]  Susan M. Schlenner,et al.  Regulatory T‐cell stability and functional plasticity in health and disease , 2022, Immunology and cell biology.

[3]  A. Rajesh,et al.  Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2 , 2022, Journal of Cancer Research and Clinical Oncology.

[4]  R. Bekkers,et al.  Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy , 2022, Journal of clinical medicine.

[5]  L. Sadler,et al.  Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. , 2021, American journal of obstetrics and gynecology.

[6]  Bin Yu,et al.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[7]  A. Karube,et al.  Progression of cervical intraepithelial neoplasia grade 2 lesions among Japanese women harboring different genotype categories of high-risk human papillomaviruses , 2021, Journal of rural medicine : JRM.

[8]  J. Taube,et al.  Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas , 2020, Cancer Immunology, Immunotherapy.

[9]  K. Simpson,et al.  Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[10]  A. Orr,et al.  Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance , 2019, Journal of Virology.

[11]  Akintunde Akinleye,et al.  Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.

[12]  L. Villa,et al.  Indoleamine 2,3‐dioxygenase and tryptophan 2,3‐dioxygenase expression in HPV infection, SILs, and cervical cancer , 2019, Cancer cytopathology.

[13]  L. Sadler,et al.  Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013–2016) , 2018, Papillomavirus research.

[14]  G. Kenter,et al.  Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer , 2018, Front. Immunol..

[15]  M. Kyrgiou,et al.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis , 2018, British Medical Journal.

[16]  J. Doorbar Host control of human papillomavirus infection and disease. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[17]  L. Sadler,et al.  Observational Management of CIN 2 in Young Women: A Prospective Multicenter Trial , 2016, Journal of lower genital tract disease.

[18]  Cara C. Schafer,et al.  Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment , 2016, Oncotarget.

[19]  J. Doorbar,et al.  Human papillomavirus molecular biology and disease association , 2015, Reviews in medical virology.

[20]  J. Renauld,et al.  Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues , 2014, Cancer Immunology Research.

[21]  A. Blumenthal,et al.  Indoleamine 2,3-dioxygenase Activity Contributes to Local Immune Suppression in the Skin Expressing Human Papillomavirus Oncoprotein E7 , 2013, The Journal of investigative dermatology.

[22]  M. Henry,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2012, Archives of pathology & laboratory medicine.

[23]  Yong-Yeon Cho,et al.  Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. , 2011, Biochemical and biophysical research communications.

[24]  K. Münger,et al.  Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming , 2011, Proceedings of the National Academy of Sciences.

[25]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[26]  G. Visner,et al.  Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression1 , 2009, The Journal of Immunology.

[27]  P. Lambert,et al.  Human Papillomavirus Type 16 E1∧E4-Induced G2 Arrest Is Associated with Cytoplasmic Retention of Active Cdk1/Cyclin B1 Complexes , 2005, Journal of Virology.

[28]  P. Beard,et al.  E1∧E4 Protein of Human Papillomavirus Type 16 Associates with Mitochondria , 2004, Journal of Virology.

[29]  J. Doorbar,et al.  Depletion of Langerhans Cells in Human Papillomavirus Type 16-Infected Skin Is Associated with E6-Mediated Down Regulation of E-Cadherin , 2003, Journal of Virology.

[30]  B. Quade,et al.  Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia , 2001, The American journal of surgical pathology.

[31]  Fan Zhang,et al.  Cyclooxygenase-2 is overexpressed in human cervical cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[33]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[34]  S. Napthine,et al.  Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. , 1997, Virology.

[35]  humAn cArcinogens,et al.  iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns , 2012 .